Avneesh Burman

Hi, good evening. Thanks for taking my question. I had a question on this new PCSK9 inhibitor. I do not know whether this was answered or not. But my question is about this new Amsterdam product called Obicetrapib. And how do you think , when it gets launched in the two years hence, how does it compete with be mpedoic acid, given the fact that the results and the trials have been pretty encouraging for this product?

Okay, thanks. That helps. Just one question is regarding the contrast media. I mean, I know that second quarter was marred by some transit issues. But if you look at the nine -months revenue and compare it, the growth is flat. So, when do we expect like a material double-digit growth here, if that is possible?

Yes. You talked about this one, the NCE product. Can you also talk a little bit about the iodinated CM product, I mean, what could be the realizations here? And what are the target volumes here and timelines, I mean, when can we see commercial launch for this product?